Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Berzosertib + Gemcitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Berzosertib | VX-970|VE-822|M6620 | ATR Inhibitor 13 | Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490). | |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 13 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | ovarian serous carcinoma | not applicable | Berzosertib + Gemcitabine | Phase II | Actionable | In a Phase II trial, the combination of Berzosertib (VX-970) and Gemzar (gemcitabine) resulted in improved median progression-free survival (22.9 vs 14.7 weeks), median overall survival (59.4 vs 43.0 weeks), and clinical benefit rate (35% (12/34) vs 25% (9/36)), and a lower objective response rate (3% (1/34) vs 11% (4/36) compared to Gemzar (gemicitabine) alone in patients with platinum-resistant high-grade serous carcinoma of the ovary, fallopian tube, or primary peritoneum (PMID: 32553118; NCT02595892). | 32553118 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02157792 | Phase I | Berzosertib + Irinotecan Berzosertib + Cisplatin + Gemcitabine Berzosertib + Cisplatin + Etoposide Berzosertib + Cisplatin Berzosertib + Carboplatin + Cisplatin Berzosertib + Gemcitabine | M6620 First in Human Study | Completed | USA | 1 |